中国口腔颌面外科杂志 ›› 2026, Vol. 24 ›› Issue (2): 114-121.doi: 10.19438/j.cjoms.2026.02.003

• 论著 • 上一篇    下一篇

基于生物靶区的老年局部晚期颌面部腺源性恶性肿瘤近距离放疗效果评价

丁紫雪1, 庄乾伟1, 葛良玉1, 徐欣晨1, 邵翠玲1,*, 孟箭1,2,*   

  1. 1.徐州市中心医院 口腔科,江苏 徐州 221000;
    2.徐州医科大学口腔医学院,江苏 徐州 221004
  • 收稿日期:2025-02-20 修回日期:2025-05-26 出版日期:2026-03-20 发布日期:2026-04-02
  • 通讯作者: 邵翠玲,E-mail: 442318105@qq.com;孟箭,E-mail: mrocket@126.com。*共同通信作者
  • 作者简介:丁紫雪(1992—),女,硕士研究生,E-mail: dingzixue@126.com
  • 基金资助:
    国家口腔疾病临床医学研究中心开放课题(NCRCO-202101);江苏省卫健委老年健康科研项目-面上项目(LKM2024031);徐州市重点研发计划(KC21187);徐州医科大学附属医院科技发展基金(XYFM202405)

Study on brachytherapy for elderly local advanced maxillofacial adenogenic malignancies based on biological target area

Ding Zixue1, Zhuang Qianwei1, Ge Liangyu1, Xu Xinchen1, Shao Cuiling1, Meng Jian1,2   

  1. 1. Department of Stomatology, Xuzhou Central Hospital. Xuzhou 221000;
    2. School of Stomatology, Xuzhou Medical University. Xuzhou 221004, Jiangsu Province, China
  • Received:2025-02-20 Revised:2025-05-26 Online:2026-03-20 Published:2026-04-02

摘要: 目的: 探讨基于18F-FDG PET-CT勾画的生物靶区(biological target volume,BTV)在老年局部晚期颌面部腺源性恶性肿瘤近距离放疗中的应用价值,比较其与增强CT勾画的大体肿瘤区(gross tumor volume,GTV)的差异及对治疗效果的影响。方法: 纳入2019年6月—2022年6月徐州市中心医院18例老年颌面部腺源性恶性肿瘤患者,术前行18F-FDG PET-CT及颌面部增强CT检查,将影像资料导入近距离治疗计划系统(brachytherapy planning system,BTPS),分别勾画BTV和GTV。患者随机分为试验组(按BTV植入125I粒子)和对照组(按GTV植入),比较两组靶区体积、术后剂量分布、近期疗效及并发症发生率。结果: BTV体积为(49.15±5.37)cm3,显著小于GTV的(52.36±3.53)cm3P<0.05)。两组术后D90(靶区达到90%的处方剂量)、D100(靶区达到100%的处方剂量)、平均剂量及V100(100%靶区体积的处方剂量)差异无统计学意义(P>0.05)。术后12个月,两组有效率分别为100%和100%,临床收益率均为100%,无显著差异(P>0.05)。两组均未出现4级放疗反应,局部症状经对症处理后缓解。结论: 基于18F-FDG PET-CT 勾画的生物靶区可缩小肿瘤靶区范围,在保证靶区剂量的同时减轻放射性损伤,不影响治疗效果,为老年局部晚期颌面部腺源性恶性肿瘤的近距离放疗提供了更精准的靶区勾画方法。

关键词: 颌面部, 腺源性恶性肿瘤, 近距离放疗, 18F-FDG PET-CT, 生物靶区, 靶区勾画

Abstract: PURPOSE: To explore the application value of biological target volume(BTV) delineated by 18F-FDG PET-CT in brachytherapy for elderly patients with locally advanced maxillofacial adenogenic malignant tumors, and to compare the differences from gross tumor volume (GTV) delineated by contrast-enhanced CT and their impacts on treatment outcomes. METHODS: Eighteen elderly patients with maxillofacial adenogenic malignant tumors admitted to Xuzhou Central Hospital from June 2019 to June 2022 were enrolled. Preoperative 18F-FDG PET-CT and maxillofacial contrast-enhanced CT were performed, and imaging data were imported into the brachytherapy planning system(BTPS) to delineate BTV and GTV, respectively. The patients were randomly divided into the experimental group (implanted with 125I seeds according to BTV) and the control group (implanted according to GTV). Target volume, postoperative dose distribution, short-term efficacy, and complications were compared between the two groups. RESULTS: The volume of BTV was (49.15±5.37) cm3, which was significantly smaller than that of GTV[(52.36±3.53) cm3](P<0.05). There were no significant differences in postoperative D90, D100, mean dose, and V100 between the two groups(P>0.05). Within 12 months after surgery, the effective rates of the two groups were both 100%, and the clinical benefit rates were both 100%, with no significant difference(P>0.05). No grade 4 radiation reactions occurred in either group, and local symptoms were relieved after symptomatic treatment. CONCLUSIONS: The biological target volume delineated by 18F-FDG PET-CT can reduce the range of tumor target volume, alleviate radiation damage while ensuring target dose, and does not affect the treatment effect, providing a more precise target delineation method for brachytherapy of elderly patients with locally advanced maxillofacial adenogenic malignant tumors.

Key words: Maxillofacial region, Adenogenic malignant tumor, Brachytherapy, 18F-FDG PET-CT, Biological target volume, Target delineation

中图分类号: